Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Things You Should Expect in Pfizer's Q4 Earnings Update

By Keith Speights - Updated Apr 23, 2019 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good, the bad, and the in-between for the big drugmaker's forthcoming earnings announcement.

Pfizer ( PFE 2.32% ) gave good news and bad news when it reported third-quarter results in October. The big drugmaker beat Wall Street's earnings estimates, but it missed on revenue expectations.

Another quarterly update is just around the corner. On Tuesday, Jan. 29, Pfizer will announce its fourth-quarter and full-year 2018 results. Here are three things you should expect in the pharma company's Q4 update.

Brightly colored pills on a pile of paper money

Image source: Getty Images.

1. Mixed results for key blockbusters

Pfizer currently has 10 blockbuster products in its lineup. It's likely that the company will report mixed results for these top performers.

On the positive side, sales for cancer drug Ibrance will almost certainly continue to increase on a year-over-year basis, thanks to uptake in international markets. Anticoagulant Eliquis, which Pfizer co-markets with Bristol-Myers Squibb, is another surefire winner for Q4. Immunology drug Xeljanz should also see a sales boost, especially as it's picking up steam in expanded indications, in psoriatic arthritis and ulcerative colitis.

There's a good chance that smoking-cessation product Chantix and longtime mainstays Lipitor and Norvasc will also keep up their momentum. The latter two drugs are well past their prime in the U.S. and Europe, but are enjoying solid sales growth in China.

What about the negatives? Although Pfizer won a six-month extension on U.S. patent exclusivity for Lyrica, slipping sales outside of the U.S. will probably drag down overall revenue for the drug. Sales for immunology drug Enbrel and cancer chemotherapy agent Sutent are also likely to continue falling.

There's a question mark on Pfizer's top-selling product, Prevnar 13. Sales for the pneumococcal vaccine jumped 9% year over year in Q3. However, much of this increase came in the U.S., primarily because of the timing of government purchases. Help from the timing of purchases in one quarter can sometimes hurt in the next quarter.

2. A bigger hit from foreign exchange rates

Pfizer narrowed its full-year 2018 revenue guidance in October, lowering the top end of its range from $55 billion to $53.7 billion. One of the key factors cited for this revision was the negative impact of foreign exchange rates, particularly the strength of the U.S. dollar from mid-July through mid-October.

It won't be surprising if Pfizer's Q4 revenue takes an even bigger hit than anticipated from foreign exchange rates. The U.S. dollar was even stronger in relation to the euro in October, November, and much of December than it was in the third quarter.

Note, however, that while the foreign exchange fluctuations could impact revenue, Pfizer's earnings might not be negatively affected. In Q3, foreign exchange helped reduce the company's adjusted cost of sales. As a result, Pfizer's adjusted earnings per share were actually boosted by the positive impact of foreign exchange.

3. No relief from nagging headwinds

Don't expect the key headwinds that plagued Pfizer throughout 2018 to have died down when the company reports its Q4 results. In particular, Pfizer's sales of sterile injectables will likely continue to slide.

But didn't former Pfizer CEO Ian Read say on the company's Q2 conference call that the sterile injectables business would show year-over-year improvement in the latter part of 2018? Yes, he did. However, Read actually said that the company expected improvement to be seen in both the third and fourth quarters. That wasn't the case in Q3, and likely won't be so in Q4 either.

By Pfizer's Q3 conference call, Read had changed his tune a bit. He said that the company expects the product shortage issues causing problems for its sterile injectables unit to be "significantly improved by the end of 2019."

Looking ahead

There's one other thing you can expect in Pfizer's Q4 update -- continued optimism about the company's long-term prospects. New CEO Albert Bourla will no doubt talk up Pfizer's pipeline, which includes a strong roster of candidates and potentially up to 15 blockbuster drugs.

Bourla and other Pfizer executives will also likely point to Pfizer's opportunities after 2020. That's when the company won't have the negative year-over-year comparisons from the coming sales drop-off for Lyrica.

Whatever Pfizer's Q4 results are, the loss of exclusivity for Lyrica will soon be a big problem. On the other hand, whatever the company's Q4 results are, Pfizer's long-term future continues to look pretty good.

Check out the latest Pfizer earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$54.27 (2.32%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.